KNTE

NASDAQ

Kinnate Biopharma Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2020

$2.65-0.01 (-0.38%)

News25/Ratings5

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. It develops KIN-2787, which is a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Diego, California.

Latest news

25 items

736dSEC
SEC Form 15-12G filed by Kinnate Biopharma Inc.
15-12G - Kinnate Biopharma Inc. (0001797768) (Filer)
748dINSIDER
Tananbaum James B. returned 13,718,311 shares to the company (SEC Form 4)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
748dINSIDER
Krishnamohan Neha returned 64,087 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
748dINSIDER
SEC Form 4 filed by Mitchell Dean J
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
748dINSIDER
Farzan Nima returned 2,186 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
748dINSIDER
SEC Form 4 filed by Epperly Melissa B,
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
748dINSIDER
SEC Form 4 filed by Smaldone Alsup Laurie
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
748dINSIDER
Flaherty Keith T. returned 66,377 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
748dINSIDER
SEC Form 4 filed by Sabzevari Helen
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
748dINSIDER
SEC Form 4 filed by Rome Michael E
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
748dINSIDER
Meltz Mark A returned 27,578 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
748dINSIDER
SEC Form 4 filed by Desimone Jill
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
748dINSIDER
Gordon Carl L returned 8,009,729 shares to the company (SEC Form 4)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
748dINSIDER
Orbimed Advisors Llc returned 8,009,729 shares to the company (SEC Form 4)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
748d13D/G
SEC Form SC 13D/A filed by Kinnate Biopharma Inc. (Amendment)
SC 13D/A - Kinnate Biopharma Inc. (0001797768) (Subject)
748dINSIDER
Foresite Capital Management Iv, Llc returned 13,718,311 shares to the company (SEC Form 4)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
750dSEC
SEC Form S-8 POS filed by Kinnate Biopharma Inc.
S-8 POS - Kinnate Biopharma Inc. (0001797768) (Filer)
750dSEC
SEC Form S-8 POS filed by Kinnate Biopharma Inc.
S-8 POS - Kinnate Biopharma Inc. (0001797768) (Filer)
750dSEC
SEC Form S-8 POS filed by Kinnate Biopharma Inc.
S-8 POS - Kinnate Biopharma Inc. (0001797768) (Filer)
750dSEC
SEC Form POSASR filed by Kinnate Biopharma Inc.
POSASR - Kinnate Biopharma Inc. (0001797768) (Filer)
750dSEC
Kinnate Biopharma Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant
8-K - Kinnate Biopharma Inc. (0001797768) (Filer)
750dSEC
SEC Form SC 14D9/A filed by Kinnate Biopharma Inc. (Amendment)
SC 14D9/A - Kinnate Biopharma Inc. (0001797768) (Subject)
750dSEC
SEC Form 25-NSE filed by Kinnate Biopharma Inc.
25-NSE - Kinnate Biopharma Inc. (0001797768) (Subject)
750dSEC
SEC Form SC TO-T/A filed by Kinnate Biopharma Inc. (Amendment)
SC TO-T/A - Kinnate Biopharma Inc. (0001797768) (Subject)
750dPR
XOMA Corporation Announces Closing of Tender Offer
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) common stock for a price per share of $2.5879 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Price") representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate p